A Randomized, Double-blind, Placebo-controlled, Dose-escalating, Single-dose, Oral Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Flonoltinib Maleate Tablets in Healthy Adult Subjects in China
Latest Information Update: 09 Oct 2025
At a glance
- Drugs Flonoltinib maleate (Primary)
- Indications COVID 2019 infections; Haemophagocytic lymphohistiocytosis; Myelofibrosis; Myeloproliferative disorders
- Focus Pharmacokinetics
- Sponsors Chengdu Zenitar Biomedical Technology
Most Recent Events
- 18 Sep 2025 Status changed from recruiting to completed.
- 05 May 2024 New trial record